Sanofi-a Ventis Deutschland Gmbh

Sanofi

Hanmi Pharm. Co., Ltd.

Marcus Korn

Stefan Guessregen

Sung Youb Jung

Georg Tschank

Thomas F Boehme

In Young Choi

Guenter Mueller

Norbert Tennagels

Ulrich Werner

Thomas Boehme

Rudolf Schneider

Laurent Bialy

Nils Rackelmann

Michael Podeschwa

Martin Will

Ana Villar Garea

Melissa Besenius

Maria Mendez Perez

Jens Riedel

The present invention relates to a conjugate comprising a sulfonamide of formula (I) and an active pharmaceutical ingredient such as an insulin analog comprising at least one mutation relative to the parent insulin, wherein the insulin analog comprises a mutation at position B16 which is substituted with a hydrophobic amino acid and/or a mutation at position B25 which is substituted with a hydrophobic amino acid. The present invention further relates to a sulfonamide of formula (A). Moreover, the present invention relates to an insulin analog comprising at least one mutation relative to the parent insulin.

Insulin conjugates

The present invention relates to a novel insulin analog, use thereof, and a method for preparing the analog.

Insulin analogs with reduced affinity to insulin receptor and use thereof

The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

PIM-3 kinase as a target for type 2 diabetes mellitus

Growing community of inventors

Frankfurt am Main, Germany

Marcus Korn